Bristol Myers Squibb Company $BMY Shares Acquired by Vontobel Holding Ltd.

Vontobel Holding Ltd. boosted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 4.3% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 725,587 shares of the biopharmaceutical company’s stock after buying an additional 29,767 shares during the period. Vontobel Holding Ltd.’s holdings in Bristol Myers Squibb were worth $41,808,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Northwestern Mutual Investment Management Company LLC lifted its holdings in Bristol Myers Squibb by 0.3% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 65,046 shares of the biopharmaceutical company’s stock valued at $3,509,000 after acquiring an additional 172 shares during the last quarter. KCM Investment Advisors LLC grew its stake in shares of Bristol Myers Squibb by 0.8% in the 4th quarter. KCM Investment Advisors LLC now owns 20,871 shares of the biopharmaceutical company’s stock worth $1,126,000 after purchasing an additional 174 shares during the last quarter. Sandy Cove Advisors LLC raised its holdings in shares of Bristol Myers Squibb by 4.7% in the 2nd quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company’s stock worth $227,000 after purchasing an additional 176 shares in the last quarter. Investment Research Partners LLC lifted its stake in Bristol Myers Squibb by 1.4% during the fourth quarter. Investment Research Partners LLC now owns 13,134 shares of the biopharmaceutical company’s stock valued at $708,000 after purchasing an additional 179 shares during the last quarter. Finally, ESG Planning DBA Harper Investing lifted its stake in Bristol Myers Squibb by 1.3% during the fourth quarter. ESG Planning DBA Harper Investing now owns 13,811 shares of the biopharmaceutical company’s stock valued at $745,000 after purchasing an additional 180 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

BMY has been the topic of several recent research reports. Raymond James Financial began coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “strong-buy” rating on the stock. Roth Capital initiated coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “buy” rating and a $75.00 price objective for the company. Royal Bank Of Canada raised their price objective on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a research note on Friday, July 31st. Argus upgraded Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 target price on the stock in a report on Wednesday, August 5th. Finally, Piper Sandler started coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set an “overweight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb has an average rating of “Moderate Buy” and a consensus price target of $66.06.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The U.S. FDA granted accelerated approval to ZENBEXUS, Bristol Myers Squibb’s first CELMoD therapy, in combination with daratumumab, hyaluronidase-fihj and dexamethasone for multiple myeloma patients as early as first relapse. The approval is strategically important because CELMoD drugs could help extend and rejuvenate the company’s important blood-cancer franchise. Bristol Myers wins milestone FDA approval of myeloma drug acquired from Celgene
• Positive Sentiment: Zacks Research raised its Bristol Myers Squibb EPS outlook for fiscal 2027 to $6.20 from $5.93. It also increased estimates for the fourth quarter of 2026, the first and second quarters of 2027, and the first two quarters of 2028, suggesting improved analyst expectations for earnings momentum.
• Positive Sentiment: The company expanded its kidney-disease pipeline with a Phase 1 study of golcadomide, providing another potential long-term growth opportunity beyond its established oncology products. Bristol-Myers Squibb expands kidney pipeline with new golcadomide renal study
• Neutral Sentiment: Rumors of a potential AstraZeneca-Bristol Myers Squibb merger have generated investor concern. Although a transaction could create a sizable oncology-focused pharmaceutical company, the strategic, financial and execution risks remain uncertain, and no deal was confirmed. Reported AstraZeneca-Bristol Myers Squibb megamerger
• Negative Sentiment: A federal appeals court revived a $6.7 billion lawsuit alleging Bristol Myers Squibb delayed approval of drugs acquired through Celgene, including Breyanzi. The case could create substantial financial liability and legal uncertainty. Lawsuit against Bristol Myers over delayed cancer drug is revived

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $63.86 on Friday. The company has a 50-day moving average of $59.56 and a two-hundred day moving average of $58.97. The stock has a market cap of $130.45 billion, a price-to-earnings ratio of 14.07, a PEG ratio of 0.17 and a beta of 0.22. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.10.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm’s revenue was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts expect that Bristol Myers Squibb Company will post 6.96 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.9%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s payout ratio is 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.